Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer (vol 18, pg 758, 2012)

被引：0
|
作者：
Sun, Jessica D.
Liu, Qian
Wang, Jingli
Ahluwalia, Dharmendra
Ferraro, Damien
Wang, Yan
Duan, Jian-Xin
Ammons, W. Steve
Curd, John G.
Matteucci, Mark D.
Hart, Charles P.
机构：
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 10期
关键词：
D O I：
10.1158/1078-0432.CCR-24-1058
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2287 / 2287
页数：1
相关论文
共 50 条
  • [41] TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
    Liu, Qian
    Sun, Jessica D.
    Wang, Jingli
    Ahluwalia, Dharmendra
    Baker, Amanda F.
    Cranmer, Lee D.
    Ferraro, Damien
    Wang, Yan
    Duan, Jian-Xin
    Ammons, W. Steve
    Curd, John G.
    Matteucci, Mark D.
    Hart, Charles P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1487 - 1498
  • [42] A first-in-man phase I study of TH-302, a hypoxia-activated cytotoxic prodrug
    Weiss, G. J.
    Infante, J. R.
    Borad, M.
    Langmuir, V. K.
    Kroll, S.
    Jung, D.
    Tibes, R.
    Chiorean, E. G.
    Jones, S. F.
    Burris, H. A.
    EJC SUPPLEMENTS, 2008, 6 (12): : 129 - 130
  • [43] Final results of a phase I study of TH-302, a hypoxia-activated cytotoxic prodrug (HAP)
    Bendell, J. C.
    Weiss, G. J.
    Infante, J. R.
    Chiorean, E. G.
    Borad, M.
    Tibes, R.
    Jones, S. F.
    Langmuir, V. K.
    Kroll, S.
    Burris, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] DNA repair processes involved with the hypoxia-activated prodrug TH-302: comparison to cisplatin and temozolomide
    Meng, Fanying
    Bhupathi, Deepthi
    Hart, Charles P.
    CANCER RESEARCH, 2015, 75
  • [45] TH-302, a tumor selective hypoxia activated prodrug, complements and enhances chemotherapy treatment with gemcitabine, docetaxel, pemetrexed, and doxorubicin
    Hart, C. P.
    Borad, M.
    Chawla, S. P.
    Infante, J. R.
    Ganjoo, K. N.
    Langmuir, V. K.
    Kroll, S.
    Curd, J. G.
    EJC SUPPLEMENTS, 2010, 8 (07): : 124 - 124
  • [46] Selective Thrombosis of Tumor for Enhanced Hypoxia-Activated Prodrug Therapy
    Ma, Zhaoyu
    Zhang, Yifan
    Dai, Xinxin
    Zhang, Weiyun
    Foda, Mohamed F.
    Zhang, Jin
    Zhao, Yanli
    Han, Heyou
    ADVANCED MATERIALS, 2021, 33 (41)
  • [47] Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias
    Konopleva, Marina
    Handisides, Damian
    Lorente, Gustavo A.
    Benito, Juliana M.
    Richie, Mary Ann
    Borthakur, Gautam
    Jabbour, Elias
    Faderl, Stefan
    Cortes, Jorge E.
    Kroll, Stewart
    Andreeff, Michael
    Kantarjian, Hagop
    Thomas, Deborah A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts
    Zhang, Xiaomeng
    Wojtkowiak, Jonathan W.
    Martinez, Gary V.
    Cornnell, Heather H.
    Hart, Charles P.
    Baker, Amanda F.
    Gillies, Robert
    PLOS ONE, 2016, 11 (05):
  • [49] Safety and activity of TH-302, a hypoxia-activated cytotoxic prodrug (HAP), in patients with metastatic melanoma and lung cancer
    Weber, R. W.
    Weiss, G. J.
    Chiorean, E. G.
    Senzer, N. N.
    Borad, M. J.
    Markovic, S.
    Molina, J. R.
    Langmuir, V. K.
    Lee, H.
    Infante, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302
    Weiss, Glen J.
    Lewandowski, Karen
    Oneall, Jon
    Kroll, Stew
    DERMATOLOGY REPORTS, 2011, 3 (03) : 128 - 129
12345